Eli Lilly and Company (NYSE:LLY) major shareholder Lilly Endowment Inc sold 180,000 shares of the business’s stock in a transaction that occurred on Thursday, August 31st. The stock was sold at an average price of $81.06, for a total value of $14,590,800.00. Following the sale, the insider now owns 123,865,804 shares of the company’s stock, valued at approximately $10,040,562,072.24. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Major shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Lilly Endowment Inc also recently made the following trade(s):

  • On Monday, July 31st, Lilly Endowment Inc sold 220,000 shares of Eli Lilly and stock. The stock was sold at an average price of $83.09, for a total value of $18,279,800.00.
  • On Thursday, June 22nd, Lilly Endowment Inc sold 210,000 shares of Eli Lilly and stock. The stock was sold at an average price of $84.43, for a total value of $17,730,300.00.
  • On Tuesday, June 20th, Lilly Endowment Inc sold 215,000 shares of Eli Lilly and stock. The stock was sold at an average price of $83.05, for a total value of $17,855,750.00.

Shares of Eli Lilly and Company (NYSE LLY) traded down 1.49% on Friday, reaching $80.08. 4,327,604 shares of the company’s stock traded hands. Eli Lilly and Company has a 52-week low of $64.18 and a 52-week high of $86.72. The firm’s 50-day moving average is $81.51 and its 200-day moving average is $81.98. The stock has a market cap of $84.48 billion, a price-to-earnings ratio of 34.65 and a beta of 0.34.

Eli Lilly and (NYSE:LLY) last posted its quarterly earnings results on Tuesday, July 25th. The company reported $1.11 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.05 by $0.06. Eli Lilly and had a net margin of 11.12% and a return on equity of 28.71%. The business had revenue of $5.82 billion during the quarter, compared to analyst estimates of $5.60 billion. During the same period in the prior year, the business posted $0.86 earnings per share. The company’s revenue was up 7.8% on a year-over-year basis. Analysts anticipate that Eli Lilly and Company will post $4.16 EPS for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Friday, September 8th. Investors of record on Tuesday, August 15th will be given a dividend of $0.52 per share. The ex-dividend date of this dividend is Friday, August 11th. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.56%. Eli Lilly and’s dividend payout ratio is 90.04%.

ILLEGAL ACTIVITY WARNING: This piece was first published by American Banking News and is the property of of American Banking News. If you are reading this piece on another domain, it was copied illegally and reposted in violation of United States and international copyright & trademark law. The correct version of this piece can be accessed at https://www.americanbankingnews.com/2017/09/01/insider-selling-eli-lilly-and-company-lly-major-shareholder-sells-180000-shares-of-stock.html.

Institutional investors have recently modified their holdings of the company. M Holdings Securities Inc. bought a new position in shares of Eli Lilly and during the second quarter worth $234,000. Achmea Investment Management B.V. raised its position in shares of Eli Lilly and by 70.6% in the second quarter. Achmea Investment Management B.V. now owns 54,884 shares of the company’s stock worth $4,515,000 after buying an additional 22,714 shares in the last quarter. Aldebaran Financial Inc. raised its position in shares of Eli Lilly and by 16.7% in the second quarter. Aldebaran Financial Inc. now owns 5,950 shares of the company’s stock worth $490,000 after buying an additional 850 shares in the last quarter. RNC Capital Management LLC raised its position in shares of Eli Lilly and by 6.6% in the second quarter. RNC Capital Management LLC now owns 452,866 shares of the company’s stock worth $37,271,000 after buying an additional 28,133 shares in the last quarter. Finally, Sentry Investment Management LLC raised its position in shares of Eli Lilly and by 0.7% in the second quarter. Sentry Investment Management LLC now owns 77,668 shares of the company’s stock worth $6,392,000 after buying an additional 506 shares in the last quarter. Hedge funds and other institutional investors own 75.77% of the company’s stock.

A number of research firms have recently weighed in on LLY. Zacks Investment Research upgraded shares of Eli Lilly and from a “hold” rating to a “buy” rating and set a $94.00 price target for the company in a research report on Monday, July 17th. Piper Jaffray Companies reiterated a “buy” rating and issued a $103.00 price target on shares of Eli Lilly and in a research report on Thursday. Jefferies Group LLC restated a “buy” rating and set a $89.00 price objective (down from $94.00) on shares of Eli Lilly and in a research report on Thursday, August 24th. Berenberg Bank restated a “buy” rating and set a $100.00 price objective on shares of Eli Lilly and in a research report on Thursday, July 27th. Finally, BidaskClub upgraded shares of Eli Lilly and from a “sell” rating to a “hold” rating in a research report on Wednesday, June 14th. Three investment analysts have rated the stock with a sell rating, seven have given a hold rating and twelve have given a buy rating to the company. The company currently has an average rating of “Hold” and an average price target of $88.07.

Eli Lilly and Company Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Insider Buying and Selling by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.